Risultati della ricerca - G. N. Hortobágyi
- Mostra 1 - 11 risultati su 11
-
1
-
2
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review... di Bryan T. Hennessy, Alain Gauthier, Laura Boehnke Michaud, G. N. Hortobagyi, Vicente Valero
Pubblicazione 2005Revisão -
3
Risk of Cardiac Death After Adjuvant Radiotherapy for Breast Cancer di Sharon H. Giordano, Yong‐Fang Kuo, J. L. Freeman, Thomas A. Buchholz, G. N. Hortobágyi, James S. Goodwin
Pubblicazione 2005Revisão -
4
-
5
-
6
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications di Neslihan Cabıoğlu, Ayşegül A. Şahin, Paolo Morandi, F. Meric-Bernstam, R. Islam, Lin Hui, C D Bucana, Ana M. González-Angulo, G. N. Hortobágyi, Massimo Cristofanilli
Pubblicazione 2009Artigo -
7
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer di Neslihan Cabıoğlu, Yun Yun Gong, R. Islam, Kristine Broglio, Nour Sneige, Ayşegül A. Şahin, Ana M. González-Angulo, Paolo Morandi, C Bucana, G. N. Hortobágyi, Massimo Cristofanilli
Pubblicazione 2007Artigo -
8
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy di Hope S. Rugo, G. N. Hortobágyi, James C. Yao, Marianne Pavel, Alain Ravaud, David Neal Franz, François Ringeisen, Jorge D. Gallo, Nicolas Rouyrre, Oezlem Anak, Robert J. Motzer
Pubblicazione 2016Revisão -
9
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight di Daniel J. Weisenberger, Binh N. Trinh, Mihaela Campan, Sweta Sharma Saha, Tiffany I. Long, Suchitra Ananthnarayan, Gangning Liang, Francisco J. Esteva, G. N. Hortobagyi, F. McCormick, Peter A. Jones, Peter W. Laird
Pubblicazione 2008Artigo -
10
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 di Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, H. Bauly, Mona El-Hashimy, T Taran, Howard A. Burris
Pubblicazione 2014Artigo -
11
LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor recept... di G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, L. Hart, M. Campone, Katarína Petráková, Eric P. Winer, W Janni, Pierfranco Conté, David Cameron, Fabrice André, CL Arteaga, Juan Pablo Zarate, A. Chakravartty, Tanya Taran, Fabienne Le Gac, Patrizia Serra, Joyce O’Shaughnessy
Pubblicazione 2021Artigo
Strumenti per la ricerca:
Soggetti correlati
Internal medicine
Medicine
Oncology
Breast cancer
Cancer
Adverse effect
Confidence interval
Hazard ratio
Surgery
Chemotherapy
Clinical endpoint
Gastroenterology
Pathology
Tamoxifen
Biology
Chemokine
Chemokine receptor
Clinical trial
Disease
Environmental health
Everolimus
Gynecology
Metastatic breast cancer
Population
Proportional hazards model
Randomized controlled trial
Receptor
Retrospective cohort study
Alternative medicine
Bisulfite